C-Reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Myocardial infarction in humans provokes an acute phase response, and C-reactive protein (CRP), the classical acute phase plasma protein, is deposited together with complement within the infarct. The peak plasma CRP value is strongly associated with postinfarct morbidity and mortality. Human CRP binds to damaged cells and activates complement, but rat CRP does not activate complement. Here we show that injection of human CRP into rats after ligation of the coronary artery reproducibly enhanced infarct size by ∼40%. In vivo complement depletion, produced by cobra venom factor, completely abrogated this effect. Complement depletion also markedly reduced infarct size, even when initiated up to 2 h after coronary ligation. These observations demonstrate that human CRP and complement activation are major mediators of ischemic myocardial injury and identify them as therapeutic targets in coronary heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pepys, M. B., & Baltz, M. L. (1983) · Advances in Immunology · doi:10.1016/s0065-2776(08)60379-x · Cited by 1,272
Self-citationWeisman, H. F., Bartow, T., Leppo, M. K., Marsh, H. C., Carson, G. R., Concino, M. F., Boyle, M. P., Roux, K. H., Weisfeldt, M. L., & Fearon, D. T. (1990) · Science · doi:10.1126/science.2371562 · Cited by 977
The physiological structure of human C-reactive protein and its complex with phosphocholine
Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure · doi:10.1016/s0969-2126(99)80023-9 · Cited by 818 · cited 1×
“Specific inhibition of CRP binding in vivo might thus be expected to be of wide clinical benefit, and suitable compounds are currently being sought, supported by our recent description of the high resolution 3-dimensional structure of the physiological CRP–ligand complex (43).”
BackgroundSelf-citationC-REACTIVE PROTEIN FIFTY YEARS ON
Pepys, M. B. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91565-8 · Cited by 681
Self-citationVigushin, D. M., Pepys, M. B., & Hawkins, P. N. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116336 · Cited by 636
Self-citationKaplan, M. H., & Volanakis, J. E. (1974) · PubMed · Cited by 563
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity
Bickerstaff, M. C. M., Botto, M., Hutchinson, W. L., Herbert, J., Tennent, G. A., Bybee, A., Mitchell, D. A., Cook, H. T., Butler, P. J. G., Walport, M. J., et al. (1999) · Nature Medicine · doi:10.1038/9544 · Cited by 489
Self-citationInteraction of C-Reactive Protein Complexes with the Complement System
Kaplan, M. H., & Volanakis, J. E. (1974) · The Journal of Immunology · doi:10.4049/jimmunol.112.6.2135 · Cited by 405
THE PHLOGISTIC ROLE OF C3 LEUKOTACTIC FRAGMENTS IN MYOCARDIAL INFARCTS OF RATS
Hill, J. H., & Ward, P. A. (1971) · The Journal of Experimental Medicine · doi:10.1084/jem.133.4.885 · Cited by 395
The second biological revolution.
Huxley, J. S. (1946) · PubMed · Cited by 389
Cited by
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
Self-citationC-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Self-citationAdipose Tissue, Inflammation, and Cardiovascular Disease
Berg, A. H., & Scherer, P. E. (2005) · Circulation Research · doi:10.1161/01.res.0000163635.62927.34 · Cited by 2,113
The inflammatory response in myocardial infarction
Frangogiannis, N. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00434-5 · Cited by 2,011
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes
Pickup, J. C. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.813 · Cited by 1,414
“Bound CRP activates complement, colocalizes with it in human hearts during acute myocardial infraction (66), and increases infarct size after experimental coronary artery ligation (67).”
BackgroundHuman C-reactive protein: expression, structure, and function
Volanakis, J. (2001) · Molecular Immunology · doi:10.1016/s0161-5890(01)00042-6 · Cited by 926
Gershov, D., Kim, S., Brot, N., & Elkon, K. B. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.9.1353 · Cited by 695
Targeting C-reactive protein for the treatment of cardiovascular disease.
Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., et al. (2006) · Nature · doi:10.1038/nature04672 · Cited by 672
Self-citationThe immune system and cardiac repair
FRANGOGIANNIS, N. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.06.007 · Cited by 641
C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis?
Jialal, I., Devaraj, S., & Venugopal, S. K. (2004) · Hypertension · doi:10.1161/01.hyp.0000130484.20501.df · Cited by 568
Pathophysiology of Heart Failure
Tanai, E., & Frantz, S. (2015) · Comprehensive Physiology · doi:10.1002/cphy.c140055 · Cited by 552
C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle
Wang, C.-H., Li, S.-H., Weisel, R. D., Fedak, P. W. M., Dumont, A. S., Szmitko, P., Li, R.-K., Mickle, D. A. G., & Verma, S. (2003) · Circulation · doi:10.1161/01.cir.0000061916.95736.e5 · Cited by 545
Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease
Wahba, I. M., & Mak, R. H. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04071206 · Cited by 513
C-Reactive Protein Levels Correlate With Mortality and Organ Failure in Critically Ill Patientsa
Lobo, S. M. A., Lobo, F. R. M., Bota, D. P., Lopes-Ferreira, F., Soliman, H. M., Meélot, C., & Vincent, J.-L. (2003) · Chest · doi:10.1378/chest.123.6.2043 · Cited by 448
Chambers, J. C., Eda, S., Bassett, P., Karim, Y., Thompson, S. G., Gallimore, J. R., Pepys, M. B., & Kooner, J. S. (2001) · Circulation · doi:10.1161/01.cir.104.2.145 · Cited by 438
Self-citationPrognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial Infarction
Latini, R., Maggioni, A. P., Peri, G., Gonzini, L., Lucci, D., Mocarelli, P., Vago, L., Pasqualini, F., Signorini, S., Soldateschi, D., et al. (2004) · Circulation · doi:10.1161/01.cir.0000145167.30987.2e · Cited by 431
Pathophysiology of heart failure
Schwinger, R. H. G. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-302 · Cited by 428
C-Reactive Protein: An Activator of Innate Immunity and a Modulator of Adaptive Immunity
Du Clos, T. W., & Mold, C. (2004) · Immunologic Research · doi:10.1385/ir:30:3:261 · Cited by 407
Arici, M., & Walls, J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.059002407.x · Cited by 398
Dandona, P., Dhindsa, S., Ghanim, H., & Chaudhuri, A. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002101 · Cited by 386
Libby, P., & Pober, J. S. (2001) · Immunity · doi:10.1016/s1074-7613(01)00119-4 · Cited by 375
C‐reactive protein and coronary heart disease: a critical review
Casas, J. P., Shah, T., Hingorani, A. D., Danesh, J., & Pepys, M. B. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02015.x · Cited by 366
Self-citationBiomarkers of inflammation and progression of chronickidney disease
Tonelli, M., Sacks, F., Pfeffer, M., Jhangri, G. S., & Curhan, G. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00398.x · Cited by 362
Membrane complement regulatory proteins
Kim, D. D., & Song, W.-C. (2006) · Clinical Immunology · doi:10.1016/j.clim.2005.10.014 · Cited by 353
Biochemical and functional characterization of the interaction between pentraxin 3 and C1q
Nauta, A. J., Bottazzi, B., Mantovani, A., Salvatori, G., Kishore, U., Schwaeble, W. J., Gingras, A. R., Tzima, S., Vivanco, F., Egido, J., et al. (2003) · European Journal of Immunology · doi:10.1002/immu.200310022 · Cited by 349
C-reactive protein and the biology of disease
Ansar, W., & Ghosh, S. (2013) · Immunologic Research · doi:10.1007/s12026-013-8384-0 · Cited by 336
Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction
Salio, M., Chimenti, S., De Angelis, N., Molla, F., Maina, V., Nebuloni, M., Pasqualini, F., Latini, R., Garlanda, C., & Mantovani, A. (2008) · Circulation · doi:10.1161/circulationaha.107.749234 · Cited by 327
The complement system: History, pathways, cascade and inhibitors
Nesargikar, P., Spiller, B., & Chavez, R. (2012) · European Journal of Microbiology and Immunology · doi:10.1556/eujmi.2.2012.2.2 · Cited by 324
Granger, C. B., Mahaffey, K. W., Weaver, W. D., Theroux, P., Hochman, J. S., Filloon, T. G., Rollins, S., Todaro, T. G., Nicolau, J. C., Ruzyllo, W., et al. (2003) · Circulation · doi:10.1161/01.cir.0000087447.12918.85 · Cited by 323
C-reactive protein and inflammation: conformational changes affect function
Wu, Y., Potempa, L. A., El Kebir, D., & Filep, J. G. (2015) · Biological Chemistry · doi:10.1515/hsz-2015-0149 · Cited by 285
Khreiss, T., József, L., Potempa, L. A., & Filep, J. G. (2004) · Circulation · doi:10.1161/01.cir.0000125527.41598.68 · Cited by 278
Chaudhuri, A., Janicke, D., Wilson, M. F., Tripathy, D., Garg, R., Bandyopadhyay, A., Calieri, J., Hoffmeyer, D., Syed, T., Ghanim, H., et al. (2004) · Circulation · doi:10.1161/01.cir.0000116762.77804.fc · Cited by 277
Lange, L. A., Carlson, C. S., Hindorff, L. A., Lange, E. M., Walston, J., Durda, J. P., Cushman, M., Bis, J. C., Zeng, D., Lin, D., et al. (2006) · JAMA · doi:10.1001/jama.296.22.2703 · Cited by 266
Inflammation and ischaemic stroke
Muir, K. W., Tyrrell, P., Sattar, N., & Warburton, E. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32813ba151 · Cited by 264
Reduction of Bleomycin-Induced Pulmonary Fibrosis by Serum Amyloid P
Pilling, D., Roife, D., Wang, M., Ronkainen, S. D., Crawford, J. R., Travis, E. L., & Gomer, R. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.4035 · Cited by 230
“Intraperitoneal injections of SAP reach the blood within 1 h (30, 37).”
BackgroundPostprandial inflammation and endothelial dysfuction
Alipour, A., Elte, J. W. F., van Zaanen, H. C. T., Rietveld, A. P., & Cabezas, M. C. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350466 · Cited by 108
van Oostrom, A. J. H. H. M., Alipour, A., Plokker, T. W. M., Sniderman, A. D., & Cabezas, M. C. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.01.009 · Cited by 102
Strang, F., Scheichl, A., Chen, Y., Wang, X., Htun, N., Bassler, N., Eisenhardt, S. U., Habersberger, J., & Peter, K. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00539.x · Cited by 94
The Pentraxins 1975–2018: Serendipity, Diagnostics and Drugs
Pepys, M. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02382 · Cited by 67
Self-citationHeme Interacts with C1q and Inhibits the Classical Complement Pathway
Roumenina, L. T., Radanova, M., Atanasov, B. P., Popov, K. T., Kaveri, S. V., Lacroix-Desmazes, S., Frémeaux-Bacchi, V., & Dimitrov, J. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.206136 · Cited by 60
Association of fear of terror with low-grade inflammation among apparently healthy employed adults
Melamed, S., Shirom, A., Toker, S., Berliner, S., & Shapira, I. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000130963.52755.b9 · Cited by 51
Metadata
- Authors
- Griselli, M., Herbert, J., Hutchinson, W. L., Taylor, K. M., Sohail, M., Krausz, T., & Pepys, M. B.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1999-12-20
- Volume
- 190
- Issue
- 12
- Pages
- 1733-1740
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2138135866
- Cited by
- 508
- References
- 41
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.